Product Introduction :

Lorlatinib is a third-generation ALK inhibitor and can be used for subsequent treatment of patients with Crizotinib resistance, to effectively inhibit 9 mutations that are resistant to Crizotinib; it is particularly suitable for the treatment of patients with advanced NSCLC who are resistant to other ALK.
In 2018, Lorlatinib was officially approved for marketing by U.S. FDA for the treatment of ALK-positive NSCLC patients, specifically including patients whose disease conditions continue to deteriorate after treatment with Crizotinib or at least one other ALK inhibitor or those whose disease progresses after treatment with Alectinib or Ceritinib as the first ALK inhibitor therapy.
Lorlatinib has an effective rate up to 90% and an intracranial effective rate up to 75% for ALK-positive NSCLC patients who receive the initial treatment. For the ALK-positive patients who have previously received the treatment with Crizotinib, Lorlatinib has an effective rate of 69% and an intracranial effective rate of 68%.

Indications :

It is indicated for the treatment of ALK+ patients with non-small cell lung cancer (NSCLC).

Administration and Dosage :

Take this product orally at a recommended dose of 100 mg, once a day.